


Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
-2.97%
+4.30%
-3.81%
-7.11%
CMPX
Compass Therapeutics
$5.59
Strengths

Upgraded on attractively valued
CMPX Price Performance
$4.23 (+32.15%)
$3.53 (+58.36%)
$3.13 (+78.59%)
$1.42 (+293.66%)
CMPX has Extreme risk level based on volatility, sector strength, volume, investor confidence, and outlook.
Click here to check what is your level of risk
Risks Indicators

Beta greater than 1.0

Price under $5

High volatilty

CMPX overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings

Reported a strong earnings
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum
Activity
Activity
Future
Future
![]()
CMPX Analysts opinion is positive and also has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential
CMPX Street Sentiment is extremely bullish and have positive views on the near-term outlook
Average key support and resistance price levels
Login to displayWhat is CMPX current stock price?
What are CMPX stock strengths?
What is CMPX Risk Level?
What is CMPX market cap and volume?
What is CMPX current Stock IQ?
Should I buy CMPX stock right now?
Is CMPX a Strong Buy right now?
What does a 'Strong Buy' rating mean for CMPX?
What does a 'Strong Sell' rating mean for CMPX?
What factors influence CMPX's Stock IQ?
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
-2.97%
+4.30%
-3.81%
-7.11%
CMPX
Compass Therapeutics
Current Price
$5.59
Stock Insights
Strengths

Upgraded on attractively valued

CMPX Price Performance
$4.23 (+32.15%)
$3.53 (+58.36%)
$3.13 (+78.59%)
$1.42 (+293.66%)
CMPX Analysts Opinion
CMPX Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings

Reported a strong earnings
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum
Activity
Activity
Future
Future
![]()
CMPX Analysts opinion is positive and also has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential
CMPX Street Sentiment is extremely bullish and have positive views on the near-term outlook
CMPX has Extreme risk level based on volatility, sector strength, volume, investor confidence, and outlook.
Click here to check what is your level of risk
Risks Indicators

Beta greater than 1.0

Price under $5

High volatilty

Average key support and resistance price levels
CMPX Stock IQ
CMPX Latest Analysis
Compass Therapeutics Inc. (CMPX) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript.
Thu Dec 4, 2025
Compass Therapeutics Inc. (CMPX) Presents at Evercore 8th Annual Healthcare Conference Transcript.
Thu Dec 4, 2025
Citizens Initiates Coverage of Compass Therapeutics (CMPX) with Market Outperform Recommendation. Fintel reports that on December 3 2025 Citizens initiated coverage of Compass Therapeutics (NasdaqCM:CMPX) with a Market Outperform recommendation. Analyst Price Forecast Suggests 148.69% Upside
Thu Dec 4, 2025
Cantor Fitzgerald Initiates Coverage of Compass Therapeutics (CMPX) with Overweight Recommendation. Fintel reports that on December 3 2025 Cantor Fitzgerald initiated coverage of Compass Therapeutics (NasdaqCM:CMPX) with a Overweight recommendation. Analyst Price Forecast Suggests 148.69% Upside
Thu Dec 4, 2025
Canaccord Genuity Initiates Coverage of Compass Therapeutics (CMPX) with Buy Recommendation. Fintel reports that on December 3 2025 Canaccord Genuity initiated coverage of Compass Therapeutics (NasdaqCM:CMPX) with a Buy recommendation. Analyst Price Forecast Suggests 148.69% Upside
Thu Dec 4, 2025
Strong Analyst Confidence in Compass Therapeutics (CMPX) Driven by CTX-10726 Advancement. With strong three-month performance and significant upside potential Compass Therapeutics Inc. (NASDAQ:CMPX) secures a spot on our list of the 12 hot penny stocks to invest in right now. On November 10 2025 H.C. Wainwrights Joseph Pantginis reiterated a Buy rating on Compass Therapeutics Inc. (NASDAQ:CMPX) with a $24 price target. The companys advancing pipeline [….]
Mon Dec 1, 2025
Wall Street Analysts Believe Compass Therapeutics Inc. (CMPX) Could Rally 154.09%: Heres is How to Trade. The mean of analysts price targets for Compass Therapeutics Inc. (CMPX) points to a 154.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Wed Nov 26, 2025
Compass Therapeutics Inc. (CMPX) is A Buy on Wall Street on Robust Pipeline Development. Compass Therapeutics Inc. (NASDAQ:CMPX) is a must-buy penny stock to buy now. On November 10 Pipe Sandler analyst Biren Amin reiterated that Compass Therapeutics Inc. (NASDAQ:CMPX) is a Buy and set a $12 price target. The positive stance stems from the companys announcement that it has made significant progress in developing its clinical pipeline. HC [….]
Tue Nov 18, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
CMPX Stock trends
CMPX Stock performance
CMPX Stock analysis
CMPX investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.